Group 1 - Company Lifesun Pharmaceutical (SZ 002393) announced that senior management personnel Guo Xiaoyan plans to reduce her holdings by no more than approximately 11,200 shares within three months after 15 trading days from the announcement date, representing a maximum reduction of 0.0044% of the total share capital excluding shares in the repurchase account [1] - As of the report date, Lifesun Pharmaceutical's market capitalization is 5.4 billion yuan [1] - For the first half of 2025, the revenue composition of Lifesun Pharmaceutical is 100% from the pharmaceutical industry [1]

证券代码：002393 证券简称：力生制药 公告编号：2025-075 天津力生制药股份有限公司 关于公司高级管理人员减持股份预披露公告 本公司高级管理人员郭晓燕女士保证向本公司提供的信息内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有天津力生制药股份有限公司（以下简称"公司"）114,800股（占公司总股本比例 0.0446%；占公司剔除回购专用账户中股份数量后的总股本比例0.0448%）的公司高级管 理人员郭晓燕女士，计划在本公告披露之日起15个交易日后的3个月内以集中竞价方式减持 本公司股份合计不超过11,200股，拟减持股份比例不超过公司剔除回购专用账户中股份数 量后总股本的0.0044%。 公司于近日收到高级管理人员郭晓燕女士出具的《股份减持计划申请表》，现将具体 内容公告如下： | 一、拟减持股东的基本情况 | | --- | | | 担任职务 | 持股数量（股） | 占公司总股本 | 占公司剔除回购 专用账户股份数 | 其中持有无限售 | | --- | --- | --- | --- | --- ...

Core Viewpoint - The company, Lisheng Pharmaceutical, announced that its Vice President, Guo Xiaoyan, holds 114,800 shares, accounting for 0.0446% of the total share capital, and plans to reduce holdings by up to 11,200 shares within three months after the announcement [1] Summary by Categories Shareholding Information - Guo Xiaoyan's current shareholding is 114,800 shares, which represents 0.0446% of the total share capital [1] - After excluding repurchased shares, the shareholding percentage is 0.0448% [1] Reduction Plan - The planned reduction involves selling up to 11,200 shares, which constitutes 0.0044% of the total share capital after excluding repurchased shares [1] - The shares to be sold are sourced from the 2022 restricted stock incentive plan [1]

Core Viewpoint - Tianjin Development (00882) announced a new investment agreement involving its indirect non-wholly owned subsidiary, Lifesun Pharmaceutical (002393), which will invest in a fixed-income product through a financial agreement with Xingyin Wealth Management and Industrial Bank [1] Group 1 - Lifesun Pharmaceutical has entered into its eleventh financial agreement with Industrial Bank, committing a principal amount of RMB 30 million, equivalent to approximately HKD 32.82 million [1]

关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：002393 证券简称：力生制药 公告编号：2025-074 天津力生制药股份有限公司 天津力生制药股份有限公司（以下简称"公司"）于2025年3月19日召开第七届董事会第 五十次会议、2025年4月11日召开2024年度股东大会，审议通过了《关于公司2025年使用 闲置自有资金进行现金管理额度的议案》，同意公司使用额度不超过人民币10亿元闲置自 有资金购买安全性高、流动性好、主要大型商业银行或证券机构发行的短期理财产品，包 括但不限于通过银行、证券等专业理财机构购买的理财产品，期限不超过股东大会批准之 日起12个月，在上述额度及期限范围内资金滚动使用。具体内容详见公司于2025年3月21 日在巨潮资讯网(www.cninfo.com.cn）披露的《关于公司2025年使用闲置自有资金进行现 金管理额度的公告》（公告编号：2025-024）。 一、本次进行现金管理购买理财产品情况 2.理财产品发行人提示了产品包括但不限于信用风险、利率风险、市场风险、流动性风 险 ...

Group 1 - The company held its first meeting of the eighth board of directors on November 13, 2025, with all nine directors present, complying with legal and regulatory requirements [2][3][4] - Zhang Ping was elected as the chairman of the eighth board of directors, with his term starting from the date of the meeting [3][4] - The board established several specialized committees, including the Strategy and Development Committee, Nomination Committee, Compensation and Assessment Committee, and Audit Committee [5][6] Group 2 - The board approved the appointment of Wang Fujun as the general manager, with his term also starting from the date of the meeting [6][7] - Three vice general managers were appointed: Long Changfeng, Liang Jiankang, and Guo Xiaoyan, with their terms aligned with the board's term [7][8] - Wang Jiaying was appointed as the financial director, and Ma Feifei was appointed as the board secretary, both with terms starting from the meeting date [8][9] Group 3 - The board approved the appointment of Zhang Guiling as the head of the Audit and Compliance Department and Liu Zilong as the securities representative, with their terms also starting from the meeting date [10][11] - The board discussed the achievement of the first unlock condition for the 2022 stock incentive plan, allowing 14 individuals to unlock a total of 112,728 shares, representing approximately 0.0438% of the company's total shares [21][34] Group 4 - The eighth board of directors consists of nine members, including five non-independent directors and three independent directors, ensuring compliance with regulatory requirements regarding board composition [39][40] - The company confirmed that all appointed members and directors meet the qualifications and have no disqualifying conditions as per relevant laws and regulations [45][46][47][48][49][50]

Core Points - The company, Lisheng Pharmaceutical, announced the appointment of Ms. Ma Feifei as the secretary of the board of directors [1] Group 1 - The board of directors of Lisheng Pharmaceutical approved the hiring of Ms. Ma Feifei [1]

Core Points - The company announced the convening of its eighth board meeting on November 13, 2025, to review the achievement of the first unlock condition for the 2022 stock incentive plan [2] - A total of 14 individuals meet the conditions for unlocking the restricted stock, with 112,728 shares eligible for release, representing approximately 0.0438% of the company's total share capital [2]

Core Viewpoint - Lisheng Pharmaceutical (SZ 002393) announced the convening of its eighth board meeting on November 13, 2025, to discuss the appointment of the head of the audit and compliance department and other documents [1] Company Summary - Lisheng Pharmaceutical's revenue composition for the first half of 2025 is entirely from the pharmaceutical industry, accounting for 100.0% [1] - As of the report, Lisheng Pharmaceutical has a market capitalization of 5.7 billion yuan [1]

渤海证券股份有限公司 证券简称：力生制药 证券代码：002393 关于 天津力生制药股份有限公司 2022 年股权激励计划预留授予部分第一个解除限售 期条件成就事项 之 独立财务顾问报告 独立财务顾问 签署日期：二〇二五年十一月 | 第一章 释义 | | --- | | 第二章 声明 . | | 第三章 基本假设 | | 第四章 激励计划履行的相关审批程序 5 | | 第五章 独立财务顾问意见 | 第一章 释义 以下词语如无特殊说明，在本文中具有如下含义： | 力生制药、本公司、公司 | 指 | 天津力生制药股份有限公司 | | --- | --- | --- | | 渤海证券、独立财务顾 问、本独立财务顾问 | 指 | 渤海证券股份有限公司 | | 独立财务顾问报告 | 指 司 | 《渤海证券股份有限公司关于天津力生制药股份有限公 2022 年股权激励计划预留授予部分第一个解除限售期 | | | | 条件成就事项之独立财务顾问报告》 | | 激励计划（草案）、本激 励计划、本计划、 | 指 | 天津力生制药股份有限公司 2022 年限制性股票激励计划 （草案） | | | | 公司依照本计划授予激励对象的力 ...